Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30468664 | 0.90 | MEN1 (0.65) | MEN1KMT2AALOX5MAPTOXER1 | |
| SCHEMBL13245455 | 0.84 | LTB4R2 (0.60) | MEN1KMT2AALOX5MAPTOXER1 | |
| SCHEMBL4941860 | 0.80 | MEN1 (0.49) | MEN1KMT2AMAPT | |
| SCHEMBL4941857 | 0.80 | MEN1 (0.49) | MEN1KMT2AMAPT | |
| SCHEMBL23628381 | 0.78 | ALDH1A1 (0.62) | MEN1KMT2AALOX5MAPTOXER1 | |
| SCHEMBL9226059 | 0.78 | MEN1 (0.86) | MEN1KMT2AALOX5MAPT | |
| SCHEMBL9226055 | 0.78 | MEN1 (0.86) | MEN1KMT2AALOX5MAPT | |
| SCHEMBL16675710 | 0.78 | MEN1 (0.86) | MEN1KMT2AALOX5MAPT | |
| SCHEMBL31704060 | 0.78 | MEN1 (0.86) | MEN1KMT2AALOX5MAPT | |
| SCHEMBL9224625 | 0.78 | MEN1 (0.86) | MEN1KMT2AALOX5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700792-B2 | Highly active lysophosphatidic acid and method of screening therewith | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20070161604-A1 | Highly active lysophosphatidic acid and method of screening therewith | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161604-A1 | Highly active lysophosphatidic acid and method of screening therewith | LPAR2, LPAR1, LPAR6 | MEN1 2319/4885KMT2A 1325/4885ALOX5 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.